Print Page

其 他 安 全 警 示

 
Canada: Non-prescription pain relief products containing codeine are not recommended for use in people under 18 years of age (English only)
 
Health Canada announces that it is advising Canadians that people under 18 years of age should not use non-prescription pain relief products containing codeine. Non-prescription codeine-containing pain relief products were previously not recommended for children and youth under 12 years of age.

This recent action is an extension of Health Canada’s previous advice to Canadians that people under 18 years of age should not use cough and cold products that contain opioids, including codeine. Health Canada continues to encourage patients, parents and caregivers to consult with their healthcare professional about the use of prescription pain relief products containing codeine or other opioids.

These actions are a result of the Department reviewing all available information on non-prescription codeine-containing pain relief products, which demonstrated that using opioids at a young age may contribute to the development of problematic substance use later in life.

Health Canada is working with manufacturers of non-prescription pain relief products containing codeine to update their product safety information to reflect the Department’s recommendation that people under 18 years of age should not use these products.

Information for patients, parents and caregivers:
- Ask your healthcare professional about alternatives to non-prescription codeine-containing products to treat pain in people under 18 years of age.
- All health products, including non-prescription pain relief products, should be used with caution and stored out of the reach of children to prevent accidental ingestion.
- Always read the labels on your medications and any additional safety information provided by your pharmacist or other healthcare professional.
- There are alternatives to codeine-containing products available for people under 18 years of age to treat pain.

Information for healthcare professionals:
- Advise patients, parents and caregivers on the proper use of opioid-containing health products.

Please refer to the following website in Health Canada for details: http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/../73635a-eng.php

In Hong Kong, there are 357 registered pharmaceutical products containing codeine.

News related to the limitation of the use of opioid-containing cough and cold medicines to adults (18 years of age and older) was previously issued by the United States Food and Drug Administration, China National Medical Products Administration and Health Canada, and was posted on the Drug Office website on 12 Jan 2018, 7 Sep 2018 and 19 Feb 2019. Letters to inform local healthcare professionals were issued by the Department of Health (DH) on 12 Jan 2018. In Jun 2018, the Registration Committee of the Pharmacy and Poisons Board discussed the matter and decided to remain vigilant on safety update issued by other overseas drug regulatory authorities.

So far, the DH has received 4 cases of adverse drug reaction related to codeine.

The DH will remain vigilant on safety update of the drug issued by other overseas drug regulatory authorities for consideration of any action deemed necessary.

Ends/Saturday, Aug 1, 2020
Issued at HKT 13:30
 
Related Information:
Canada: Prescription cough and cold products containing opioids and the risk of ... 上載於 2020-08-25
Canada: Summary Safety Review - Opioid-containing cough and cold products - Asse... 上載於 2019-02-19
中國:國家藥品監督管理局關於修訂含可待因感冒藥說明書的公告(2018年第63號) 上載於 2018-09-07
FDA requires labeling changes for prescription opioid cough and cold medicines t... 上載於 2018-01-12
美國:食物及藥物管理局藥物安全通訊:食物及藥物管理局要求鴉片類咳嗽和感冒處方藥物更改標籤,以限制此類藥物只可用於18歲或以上成年人 上載於 2018-01-12
澳洲:安全審查:可待因用於兒童和超快速代謝者:更新 – 建議生效 上載於 2017-11-29
中國:國家食品藥品監督管理總局關於修訂含可待因藥品說明書的公告(2016年第199號) 上載於 2017-01-05
新加坡:兒童和青少年使用含可待因產品的限制 上載於 2016-12-21
澳洲:可待因產品重訂法例分類計劃的更新 -含可待因藥物轉為醫生處方藥物 上載於 2016-12-20
加拿大:新安全措施以進一步限制兒童和青少年使用處方可待因和二氫可待因酮 上載於 2016-07-29
新加坡:含可待因產品用於兒童和青少年,以治療疼痛和舒緩咳嗽和感冒的建議 上載於 2016-07-05
澳洲:安全評審:可待因用於兒童和超快速代謝者 上載於 2015-10-02
美國:可待因咳嗽和感冒藥:藥物安全通訊 - 美國食品及藥物管理局正評估嚴重副作用的潛在風險 上載於 2015-07-02
英國: 藥物安全更新:可待因作治療咳嗽和感冒:於12歲以下兒童限制使用 上載於 2015-04-30
歐洲聯盟:可待因不能用於12歲以下兒童作治療咳嗽和感冒 上載於 2015-04-25
歐洲聯盟:藥物警戒風險評估委員會建議限制可待因在小兒的咳嗽和感冒的使用 上載於 2015-03-14
新加坡:有關含可待因產品使用於紓緩兒童疼痛的海外建議 上載於 2014-09-05
歐洲聯盟:展開對含可待因的兒童咳嗽及感冒藥物的檢討 上載於 2014-04-12
有關使用可待因的最新消息 上載於 2013-06-29
歐洲聯盟:歐洲藥物監管局轄下藥物警戒風險評估委員會建議限制使用可待因紓緩兒童的疼痛 上載於 2013-06-15
加拿大:加拿大衞生部的檢討報告建議可待因只可用於12歲以上的病人 上載於 2013-06-07
可待因 - 建議只可用於12歲及12歲以上的病人(給醫護專業人員的信,內容為英文) 上載於 2013-06-07
美國:美國食品及藥物管理局藥物安全通訊:對可待因用於兒童的安全性檢討的更新資訊: 新增”扁桃腺切除術及/或腺樣增殖體切除術後使用”於黑框警告及禁忌症 上載於 2013-02-21
美國:食品及藥物管理局藥物安全通訊:某些兒童在進行扁桃腺切除術及/或腺樣增殖體切除術後使用可待因有機會引發極少,但致命的不良事件或死亡 上載於 2012-08-16
美國食品及藥物管理局:某些兒童在進行扁桃腺切除術及/或腺樣增殖體切除術後使用可待因有機會引發極少,但致命的不良事件或死亡(給醫護專業人員的信,內容為英文) 上載於 2012-08-16
 
back